Feature | May 24, 2013

InspireMD's MGuard Embolic Protection Stent Shows Lower Mortality Rate in STEMI

The six-month trial looked at 433 patients with STEMI

mGuard stent, STEMI

May 24, 2013 — InspireMD Inc. announced new six-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial demonstrating that the MGuard embolic protection stent (EPS) outperformed bare metal stents and drug-eluting stents in all-cause mortality in ST-segment elevation myocardial infarction (STEMI) patients. With its micro-net mesh sleeve, MGuard EPS prevents unstable arterial plaque and thrombus (clots) that cause heart attack blockage from breaking off and exacerbating damage.

The MASTER trial achieved its primary endpoint (p value = 0.008), in complete ST-segment resolution at 60 to 90 minutes post-procedure (a strong predictor of mortality). Secondary endpoint clinical outcomes continue to show a lower mortality rate with MGuard EPS compared to control (0.5 percent vs. 2.8 percent, P=0.06) at six months. These findings corroborate the previously announced 30-day results showing that all-cause mortality with MGuard EPS was lower than bare metal and drug-eluting stents used as a control (0 percent vs. 1.9 percent, P=0.06).  

In the MASTER trial, a total of 433 patients with STEMI presenting within 12 hours of symptom onset undergoing percutaneous coronary intervention (PCI) were randomized at 50 sites in nine countries to the MGuard EPS (n = 217) or commercially available bare metal or drug-eluting stents (n = 216).

Watch the video on InspireMD’s Micronet Technology at www.youtube.com/watch?v=EbrhcQMM7YE.

For more information: www.InspireMD.com

Related Content

Videos | Angiography| November 22, 2017
Shimadzu demonstrated its Trinias Interventional X-ray System at the 2017 Transcatheter Cardiovascular Therapeutics (
Videos | Radial Access| November 22, 2017
Mladen I.
Avinger Receives 510(k) Clearance for Pantheris Image-Guided Atherectomy Device Modifications
Technology | Atherectomy Devices| November 20, 2017
November 20, 2017 — Avinger Inc. announced in October that the company received 510(k) clearance from the U.S.
Surgery Could Reduce Frailty in Adults With Heart Failure
News | Heart Failure| November 17, 2017
November 17, 2017 — Common practice, and recently published research, shows that the risk of complications with surge
Videos | 3-D Printing| November 17, 2017
Dee Dee Wang, M.D., Director, Structural Heart Imaging at Henry Ford Hospital, Detroit, explains how her center uses
News | Antiplatelet and Anticoagulation Therapies| November 16, 2017
Bristol-Myers Squibb Company and Pfizer Inc. released real-world data (RWD) of outcomes associated with direct oral...
SPRINT Trial Data Support New AHA/ACC Hypertension Guidelines
News | Hypertension| November 16, 2017
Findings from a landmark study funded by the National Institutes of Health (NIH) support a key component of the new...
Videos | Stents Bifurcation| November 15, 2017
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morris
Videos | TCT| November 15, 2017
DAIC Editor Dave Fornell shows some of the innovations displayed on the expo floor at the 2017 Transcatheter Cardiova
Videos | FFR Technologies| November 15, 2017
A discussion with William Fearon, M.D.
Overlay Init